HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on ORIC Pharmaceuticals (NASDAQ:ORIC) and maintained a $14 price target.
June 08, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating on ORIC Pharmaceuticals and keeps $14 price target.
The Buy rating reaffirmation by HC Wainwright & Co. analyst Robert Burns indicates a positive outlook for ORIC Pharmaceuticals. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100